ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)
ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of [...]
Drugs against rare diseases
José María Mato, Óscar Millet and Joaquín Castilla present their research on Porphyria and Prion diseases, and how ATLAS molecular pharma is a clear example of translational biomedical research. Related info: Eitb.eus Radio https://vimeo.com/206707728
A possible pharmacological chaperone for congenital erythropoietic porphyria
The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. [...]
Atlas Molecular Pharma will be attending BioSpain 2016 in Bilbao, September 28th – 30th
Join us at BioSpain 2016 in Bilbao, September 28th – 30th. If you want to find out more about what we do and are a potential Investor or Partner, please contact us through the BioSpain Partnering [...]
-
CIC bioGUNE, CRB Inverbío, Kereon Partners and private investors create Atlas Molecular Pharma to discover new drugs for the treatment of Rare and Ultra-Rare diseases GalleryCIC bioGUNE, CRB Inverbío, Kereon Partners and private investors create Atlas Molecular Pharma to discover new drugs for the treatment of Rare and Ultra-Rare diseases
CIC bioGUNE, CRB Inverbío, Kereon Partners and private investors create Atlas Molecular Pharma to discover new drugs for the treatment of Rare and Ultra-Rare diseases
The new company, Atlas Molecular Pharma, will further develop its proprietary technology to act as a “drug discovery engine” for the discovery and development of drugs called pharmacological chaperones, which act by restoring defective protein [...]